US-based infectious-disease treatment developer AN2 Therapeutics has emerged from stealth with $12m of series A funding from investors including medicine provider Brii Biosciences.
The round was led by investment firm Mountain Group Partners and also featured life sciences-focused investment fund Adjuvant Capital and venture capital fund BioRock Ventures.
AN2 is working on antibacterial drugs targeting previously unexploited biological mechanisms to control outbreaks of infectious disease more effectively than existing medications. The series A funds will help advance clinical development of its lead compound as well as multiple preclinical assets.
The company is looking to drive its commercialisation strategy by seeking non-dilutive funding and strategic alliances with industry partners, having licensed the Chinese marketing rights for its lead compound to Brii Biosciences.
Eric Easom, co-founder and chief executive of AN2 Therapeutics, said: “It is an honour to be partnering with Brii Biosciences and their world-class team of scientists in the field of infectious diseases.”